Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 33 | 2025 | 370 | 9.860 |
Why?
|
| Influenza Vaccines | 22 | 2025 | 173 | 6.680 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 18 | 2024 | 87 | 4.750 |
Why?
|
| Vaccination | 15 | 2025 | 310 | 3.820 |
Why?
|
| Antibodies, Viral | 14 | 2025 | 348 | 3.160 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 10 | 2025 | 115 | 2.360 |
Why?
|
| Seasons | 10 | 2024 | 246 | 2.100 |
Why?
|
| Immunologic Memory | 6 | 2025 | 188 | 1.840 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 10 | 2025 | 83 | 1.680 |
Why?
|
| Vaccines | 5 | 2022 | 84 | 1.670 |
Why?
|
| Antigens, Viral | 9 | 2024 | 135 | 1.630 |
Why?
|
| Host-Pathogen Interactions | 8 | 2024 | 241 | 1.620 |
Why?
|
| Influenza A virus | 5 | 2025 | 177 | 1.620 |
Why?
|
| B-Lymphocytes | 7 | 2025 | 760 | 1.570 |
Why?
|
| Receptors, Antigen, B-Cell | 5 | 2025 | 108 | 1.490 |
Why?
|
| Antigenic Variation | 6 | 2024 | 28 | 1.470 |
Why?
|
| Antibodies, Neutralizing | 7 | 2025 | 163 | 1.420 |
Why?
|
| Pneumococcal Infections | 4 | 2018 | 52 | 1.380 |
Why?
|
| Orthomyxoviridae | 7 | 2020 | 48 | 1.380 |
Why?
|
| Communicable Diseases | 3 | 2023 | 69 | 1.320 |
Why?
|
| Streptococcus pneumoniae | 4 | 2018 | 56 | 1.290 |
Why?
|
| Influenza B virus | 5 | 2025 | 33 | 1.210 |
Why?
|
| Evolution, Molecular | 7 | 2018 | 891 | 1.120 |
Why?
|
| Cross Protection | 3 | 2024 | 11 | 0.990 |
Why?
|
| Selection, Genetic | 4 | 2018 | 538 | 0.980 |
Why?
|
| Epidemics | 3 | 2023 | 41 | 0.900 |
Why?
|
| Models, Biological | 7 | 2020 | 1810 | 0.890 |
Why?
|
| Age Distribution | 2 | 2021 | 210 | 0.790 |
Why?
|
| Immunogenicity, Vaccine | 4 | 2021 | 19 | 0.780 |
Why?
|
| Humans | 65 | 2025 | 95992 | 0.780 |
Why?
|
| Biological Evolution | 5 | 2021 | 1031 | 0.740 |
Why?
|
| Adaptive Immunity | 3 | 2015 | 180 | 0.730 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2020 | 13 | 0.730 |
Why?
|
| Disease Susceptibility | 4 | 2024 | 220 | 0.730 |
Why?
|
| Models, Theoretical | 4 | 2021 | 504 | 0.710 |
Why?
|
| Models, Immunological | 4 | 2018 | 85 | 0.690 |
Why?
|
| Off-Label Use | 1 | 2021 | 16 | 0.680 |
Why?
|
| Antibodies | 2 | 2023 | 356 | 0.670 |
Why?
|
| Child | 12 | 2025 | 7621 | 0.600 |
Why?
|
| Child, Preschool | 8 | 2025 | 3969 | 0.590 |
Why?
|
| Silent Mutation | 1 | 2018 | 3 | 0.560 |
Why?
|
| HIV | 1 | 2018 | 49 | 0.550 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 84 | 0.510 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.510 |
Why?
|
| Models, Statistical | 8 | 2022 | 594 | 0.510 |
Why?
|
| Humidity | 1 | 2017 | 94 | 0.500 |
Why?
|
| Carrier State | 2 | 2018 | 40 | 0.500 |
Why?
|
| Young Adult | 10 | 2025 | 7034 | 0.500 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 74 | 0.490 |
Why?
|
| Adaptation, Physiological | 3 | 2018 | 341 | 0.490 |
Why?
|
| Adolescent | 10 | 2025 | 9878 | 0.480 |
Why?
|
| Pandemics | 6 | 2022 | 880 | 0.470 |
Why?
|
| Antibody Diversity | 1 | 2015 | 25 | 0.470 |
Why?
|
| Immunodominant Epitopes | 2 | 2015 | 23 | 0.450 |
Why?
|
| Age Factors | 5 | 2025 | 1959 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.440 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.440 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 24 | 0.420 |
Why?
|
| Hong Kong | 3 | 2023 | 45 | 0.400 |
Why?
|
| Immune System | 1 | 2014 | 103 | 0.390 |
Why?
|
| Adult | 15 | 2025 | 28636 | 0.390 |
Why?
|
| Haemophilus Infections | 1 | 2012 | 9 | 0.380 |
Why?
|
| Haemophilus influenzae | 1 | 2012 | 17 | 0.380 |
Why?
|
| Incidence | 5 | 2020 | 1723 | 0.370 |
Why?
|
| Nasopharynx | 1 | 2012 | 51 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 848 | 0.350 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1309 | 0.350 |
Why?
|
| Infant | 5 | 2025 | 3359 | 0.350 |
Why?
|
| Computer Simulation | 6 | 2022 | 1158 | 0.350 |
Why?
|
| Antigens, Bacterial | 1 | 2012 | 138 | 0.350 |
Why?
|
| Aged | 12 | 2025 | 20927 | 0.350 |
Why?
|
| Animals | 14 | 2024 | 28901 | 0.330 |
Why?
|
| Host Specificity | 1 | 2010 | 13 | 0.320 |
Why?
|
| Eggs | 2 | 2021 | 13 | 0.320 |
Why?
|
| Middle Aged | 11 | 2025 | 28299 | 0.310 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 297 | 0.290 |
Why?
|
| RNA Viruses | 1 | 2008 | 8 | 0.290 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 7224 | 0.280 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 539 | 0.270 |
Why?
|
| Virus Diseases | 1 | 2008 | 102 | 0.270 |
Why?
|
| Asymptomatic Infections | 2 | 2024 | 19 | 0.270 |
Why?
|
| Antibody Formation | 2 | 2025 | 181 | 0.250 |
Why?
|
| Neutralization Tests | 2 | 2024 | 77 | 0.250 |
Why?
|
| Cross Reactions | 3 | 2018 | 115 | 0.240 |
Why?
|
| Pneumococcal Vaccines | 2 | 2018 | 33 | 0.230 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2025 | 5 | 0.230 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2025 | 66 | 0.220 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2025 | 28 | 0.220 |
Why?
|
| Neuraminidase | 1 | 2024 | 47 | 0.220 |
Why?
|
| Coinfection | 1 | 2025 | 67 | 0.210 |
Why?
|
| Basic Reproduction Number | 2 | 2022 | 6 | 0.210 |
Why?
|
| Zoonoses | 2 | 2016 | 28 | 0.210 |
Why?
|
| Female | 10 | 2025 | 49980 | 0.210 |
Why?
|
| Male | 9 | 2025 | 45792 | 0.200 |
Why?
|
| Epitopes | 3 | 2021 | 258 | 0.200 |
Why?
|
| Algorithms | 3 | 2018 | 2018 | 0.190 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2023 | 54 | 0.190 |
Why?
|
| Germ Cells | 1 | 2023 | 134 | 0.190 |
Why?
|
| Cohort Studies | 2 | 2020 | 3115 | 0.180 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 60 | 0.180 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1880 | 0.180 |
Why?
|
| Amino Sugars | 1 | 2021 | 3 | 0.180 |
Why?
|
| Ferrets | 2 | 2018 | 50 | 0.180 |
Why?
|
| New Zealand | 1 | 2021 | 24 | 0.170 |
Why?
|
| Prevalence | 3 | 2020 | 1355 | 0.170 |
Why?
|
| Viral Load | 1 | 2022 | 164 | 0.170 |
Why?
|
| Mass Vaccination | 1 | 2021 | 10 | 0.170 |
Why?
|
| Immune Evasion | 1 | 2021 | 37 | 0.170 |
Why?
|
| Health Priorities | 1 | 2021 | 28 | 0.170 |
Why?
|
| Polysaccharides | 1 | 2021 | 96 | 0.170 |
Why?
|
| Time Factors | 3 | 2019 | 5593 | 0.160 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2020 | 57 | 0.160 |
Why?
|
| Wisconsin | 1 | 2020 | 46 | 0.160 |
Why?
|
| Phylogeny | 3 | 2018 | 1277 | 0.160 |
Why?
|
| Probability | 1 | 2021 | 365 | 0.160 |
Why?
|
| United States | 6 | 2024 | 7785 | 0.160 |
Why?
|
| Immunity, Innate | 2 | 2015 | 464 | 0.160 |
Why?
|
| Alleles | 1 | 2023 | 1157 | 0.160 |
Why?
|
| Models, Genetic | 2 | 2015 | 984 | 0.160 |
Why?
|
| Microbial Interactions | 2 | 2024 | 12 | 0.150 |
Why?
|
| Hemagglutinins | 1 | 2019 | 22 | 0.150 |
Why?
|
| Vaccination Coverage | 1 | 2018 | 7 | 0.140 |
Why?
|
| Vaccines, Inactivated | 1 | 2018 | 36 | 0.140 |
Why?
|
| Amino Acid Substitution | 2 | 2018 | 336 | 0.140 |
Why?
|
| Computational Biology | 2 | 2020 | 587 | 0.140 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 74 | 0.140 |
Why?
|
| Plasma Cells | 1 | 2018 | 88 | 0.140 |
Why?
|
| Genome, Viral | 1 | 2018 | 80 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 935 | 0.140 |
Why?
|
| Sentinel Surveillance | 2 | 2022 | 23 | 0.140 |
Why?
|
| Alphapapillomavirus | 1 | 2017 | 45 | 0.130 |
Why?
|
| New York City | 1 | 2016 | 69 | 0.130 |
Why?
|
| Chicago | 2 | 2022 | 1505 | 0.120 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 647 | 0.120 |
Why?
|
| Phylogeography | 1 | 2016 | 51 | 0.120 |
Why?
|
| Genetic Variation | 3 | 2014 | 1424 | 0.120 |
Why?
|
| Clonal Selection, Antigen-Mediated | 1 | 2015 | 8 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1962 | 0.120 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 37 | 0.120 |
Why?
|
| Antibody Affinity | 1 | 2015 | 38 | 0.120 |
Why?
|
| Temperature | 1 | 2017 | 432 | 0.110 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2015 | 35 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1176 | 0.110 |
Why?
|
| Germinal Center | 1 | 2015 | 65 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 1069 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2017 | 301 | 0.100 |
Why?
|
| Species Specificity | 2 | 2012 | 708 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1191 | 0.100 |
Why?
|
| Genetics, Population | 1 | 2016 | 439 | 0.100 |
Why?
|
| Genetic Fitness | 1 | 2012 | 45 | 0.090 |
Why?
|
| Mutation | 3 | 2019 | 4374 | 0.090 |
Why?
|
| Serotyping | 1 | 2012 | 28 | 0.090 |
Why?
|
| Bacterial Capsules | 1 | 2012 | 29 | 0.090 |
Why?
|
| Population Dynamics | 1 | 2012 | 144 | 0.090 |
Why?
|
| Mice | 2 | 2023 | 12525 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3922 | 0.090 |
Why?
|
| Measles virus | 1 | 2011 | 10 | 0.090 |
Why?
|
| Seroepidemiologic Studies | 2 | 2022 | 57 | 0.090 |
Why?
|
| Genetic Heterogeneity | 1 | 2010 | 70 | 0.080 |
Why?
|
| Stochastic Processes | 1 | 2010 | 79 | 0.080 |
Why?
|
| Emigration and Immigration | 1 | 2010 | 49 | 0.080 |
Why?
|
| Receptors, Virus | 1 | 2010 | 76 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2011 | 218 | 0.080 |
Why?
|
| Illinois | 2 | 2022 | 530 | 0.080 |
Why?
|
| Cats | 1 | 2010 | 305 | 0.080 |
Why?
|
| Phenotype | 2 | 2014 | 2575 | 0.080 |
Why?
|
| Chickens | 2 | 2021 | 212 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 1006 | 0.070 |
Why?
|
| Birds | 1 | 2010 | 173 | 0.070 |
Why?
|
| World Health Organization | 2 | 2021 | 122 | 0.060 |
Why?
|
| Epidemiological Monitoring | 2 | 2016 | 43 | 0.060 |
Why?
|
| Michigan | 1 | 2025 | 57 | 0.060 |
Why?
|
| Family Characteristics | 1 | 2025 | 52 | 0.060 |
Why?
|
| Outpatients | 1 | 2022 | 105 | 0.040 |
Why?
|
| Computer Systems | 1 | 2022 | 79 | 0.040 |
Why?
|
| Biohazard Release | 1 | 2021 | 1 | 0.040 |
Why?
|
| Philadelphia | 1 | 2020 | 26 | 0.040 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2020 | 42 | 0.040 |
Why?
|
| China | 1 | 2021 | 264 | 0.040 |
Why?
|
| Forecasting | 2 | 2011 | 317 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 500 | 0.040 |
Why?
|
| Global Health | 2 | 2011 | 214 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 706 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 91 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 157 | 0.030 |
Why?
|
| Ovum | 1 | 2017 | 61 | 0.030 |
Why?
|
| Glycosylation | 1 | 2017 | 137 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1063 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2536 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 481 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 946 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2025 | 4690 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2016 | 113 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1425 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 3239 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 1231 | 0.030 |
Why?
|
| Technology, Pharmaceutical | 1 | 2013 | 36 | 0.020 |
Why?
|
| Parvovirus, Canine | 1 | 2011 | 1 | 0.020 |
Why?
|
| Disease Vectors | 1 | 2011 | 6 | 0.020 |
Why?
|
| Parvoviridae Infections | 1 | 2011 | 6 | 0.020 |
Why?
|
| Animals, Domestic | 1 | 2011 | 12 | 0.020 |
Why?
|
| Switzerland | 1 | 2011 | 19 | 0.020 |
Why?
|
| Measles | 1 | 2011 | 14 | 0.020 |
Why?
|
| Disease Reservoirs | 1 | 2011 | 23 | 0.020 |
Why?
|
| Animals, Wild | 1 | 2011 | 52 | 0.020 |
Why?
|
| Dogs | 1 | 2011 | 718 | 0.020 |
Why?
|
| Geographic Information Systems | 1 | 2010 | 28 | 0.020 |
Why?
|
| Asia | 1 | 2010 | 107 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2011 | 289 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 2498 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 978 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 10307 | 0.020 |
Why?
|
| Immunity, Herd | 1 | 2006 | 2 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3040 | 0.020 |
Why?
|
| Point Mutation | 1 | 2006 | 247 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 157 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 832 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 1883 | 0.010 |
Why?
|